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ABSTRACT
Introduction: Reported levels of adherence to prophylaxis among
young people with haemophilia (YPH) vary widely and are
predominately based on estimations made by healthcare
professionals and parents. Reasons for (non)adherence among
YPH in particular have not been evidenced.
Aim: to examine experiences in relation to prophylaxis with YPH
themselves, and barriers and facilitators to their adherence.
Methods: 11 Participants were recruited in ﬁve haemophilia
centres across England and Wales. All patients who met the
inclusion criteria (aged 12-25, diagnosed with haemophilia, on
prophylaxis) were approached during a routine check-up
appointment, and all participants who agreed to take part were
interviewed. Interviews were audio recorded, transcribed and
analysed using Interpretative Phenomenological Analysis.
Results: Self-reported adherence to prophylaxis was good. Few
participants admitted to intentionally skipping injections although
they reported sometimes forgetting. However, due to the
increasingly personalised and ﬂexible approach to prophylaxis,
adherence is not straightforward to deﬁne. Barriers to adherence
included a busy lifestyle, dislike of the intravenous injection,
venous access issues, anxiety or stress and being out of one’s
normal routine. Support was an important facilitator to adherence,
including support from health professionals at the haemophilia
centre as well as friends. Parents appear to be very involved with
their child’s haemophilia management, even after they leave home.
Conclusion: What this study adds is that the increasingly ﬂexible
and personalised approach to managing prophylaxis in
haemophilia may sometimes lead to confusion around treatment
frequency and dosing. This may lead to accidental non-adherence,
which is distinct from both skipping and forgetting. Advice from
haemophilia teams may not always be consistent and is likely to
be interpreted diﬀerently by diﬀerent individuals. Some additional
training and education of patients and their families to increase
their knowledge and skills around prophylaxis may reduce this
confusion and therefore is likely to improve adherence further.
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Introduction
Haemophilia is an inherited bleeding disorder that occurs mostly in males and is caused by
a deﬁciency in one of the coagulation (blood clotting) factors. According to the United
Kingdom Haemophilia Centre Doctors’ Organisation (UKHCDO) Annual Report,
2015/2016 there are approximately 7,700 people in the UKwith Haemophilia A (deﬁciency
in factor VIII) and 1,707 with Haemophilia B (deﬁciency in factor IX). Haemophilia is
classiﬁed as mild, moderate or severe based on the concentration of factor measured via
a blood test (Bolton-Maggs & Pasi, 2003). This study is concerned with patients with
severe haemophilia (approximately 1/3 of those with haemophilia) where the concen-
tration of factor in the blood is generally less than 1%. This results in a greater risk of spon-
taneous bleeding and excessive bleeding after injuries, accidents and surgery.
Haemophilia is treated by replacing the deﬁcient coagulation factor through intrave-
nous injections of factor concentrate. Treatment can be on-demand, where medication
is used to treat bleeding; or preventative, where treatment is used to increase the concen-
tration of factor in the blood to reduce risk of bleeding (Collins, 2012). Most patients with
severe haemophilia in the UK follow a preventative treatment regimen (known as prophy-
laxis). For each patient on prophylaxis lifetime healthcare costs are estimated at £5.98
million for haemophilia A, and £2.47 million for haemophilia B (Miners, 2009).
Prophylaxis reduces joint bleeds and resulting joint damage (Fischer et al., 2002;
Manco-Johnson et al., 2007) as well as intracranial bleeds (Ljung, 2009; Witmer et al.,
2011), whilst improving quality of life (Richards et al., 2010). Initiating prophylaxis at
an early age, often shortly after diagnosis, is the optimal form of treatment for severe hae-
mophilia (Coppola, Di Capua, & De Simone, 2008). Parents are trained to give the injec-
tions to their child at home, while children are encouraged to help from a young age (e.g.
mix up treatment ready for the injection, clean the skin, etc.), and gradually take over the
responsibility for their treatment. Haemophilia teams generally aim for patients to do their
own injections by the time they start senior school. However, the age at which patients
become responsible varies widely (Khair, 2013).
In previous decades haemophilia A prophylaxis regimens were based on patients’
weight and aimed to reduce the risk of bleeding by increasing the trough level above 1
IU dL -1, thus converting the bleeding phenotype from severe to moderate (Ahlberg,
1965; Nilsson, Berntop, Lofqvist, & Pettersson, 1992). Although this strategy was
proven to be highly successful in long-term follow-up studies (Fischer et al., 2002;
Nilsson, 1993), it is recognised that some patients bleed despite having a trough level
above 1 IU dL -1 (concentration of factor in the blood of 1% of normal), whereas
others do not bleed even with an undetectable trough level (Collins, 2012). It is likely
that the factor level required to prevent bleeding varies between patients, and that 1 IU
dL -1 is therefore not necessarily an appropriate target for all patients (Den Uijl et al.,
2011). In recent years regimens have become more ﬂexible, and many patients follow a
more individualised treatment regimen, designed around their lifestyle, planned activities,
individual bleeding pattern, condition of their musculoskeletal system, and measurement
of coagulation factor in their blood (Collins, 2012; Fischer, 2012; Makris, 2012). In
addition, many patients in the UK are encouraged to top up with an additional injection
in advance of physical activity if they feel their usual regimen will not aﬀord them enough
protection.
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Patients’ adherence, the extent to which they follow their agreed treatment regimen, has
considerable inﬂuence on treatment eﬃcacy. Non-adherence (i.e. not keeping to the
agreed frequency and/or dosing and/or timing of prophylactic injections) increases the
risk of spontaneous bleeds (Collins et al., 2009; Hacker, Geraghty, & Manco-Johnson,
2001), which increases treatment costs (Panicker, Warrier, Thomas, & Lusher, 2003),
and may result in joint damage leading to poorer physical and emotional wellbeing (du
Treil, Rice, & Leissinger, 2007; Marilyn J Manco-Johnson et al., 2007). In addition to
the immediate costs associated with treating bleeds (on-demand treatment, potential hos-
pitalisation, clinic visits, etc.), they may also lead to increased future care-costs due to dis-
ability. Even low levels of non-adherence can result in signiﬁcant medical problems and
permanent disability (du Treil et al., 2007).
A recent review (Schrijvers, Uitslager, Schuurmans, & Fischer, 2013) identiﬁed that
there is little research on adherence among people with haemophilia, with most studies
being of poor quality (based on sample size, methodology, and bias). Nevertheless, in
their review (Schrijvers et al., 2013) suggest that the key motivators of adherence to pro-
phylaxis are experience of symptoms, a positive belief of necessity of prophylaxis and a
good relationship with the healthcare provider. They suggest that the most important bar-
riers to adherence are infrequent or absence of symptoms and increasing age.
A recent study with a large sample of young people on prophylaxis (representing nearly
20% of the whole target population) who were recruited from 13 haemophilia centres
across England and Wales (van Os, Troop, Sullivan, & Hart, 2017) found adherence to
be good (over 80%). In this study adherence was predicted by a greater necessity
concern diﬀerential (where patients’ perceived the need for prophylaxis to be greater
than their concerns over taking it), and a positive expectancy of the eﬀectiveness of pro-
phylaxis, good social support and a stronger (negative) emotional reaction to having hae-
mophilia were also associated with better adherence. However, it is important to note that
measures that assess adherence in haemophilia (including the widely used VERITAS-Pro:
Duncan, Kronenberger, Roberson, & Shapiro, 2010), are based on a traditional approach
to treatment. This means their utility in the context of an increasingly ﬂexible, personal-
ised treatment is somewhat limited. For instance, patients who have agreed a more ﬂexible
approach with their haemophilia doctor, and are therefore not required to contact the hae-
mophilia centre before making one-oﬀ adjustments to their regimen, may be considered
non-adherent by the VERITAS-Pro. Furthermore, the range of predictors of adherence
used in van Os et al.’s (2017) study (including beliefs about medicines, social support
and outcome expectancies) was limited to those previously identiﬁed as predictors of
(non-)adherence in haemophilia and other chronic conditions (Gallant, 2003; Horne &
Weinman, 1999; Iannotti et al., 2006; Llewellyn, Miners, Lee, Harrington, & Weinman,
2003). Therefore, it may not have included all relevant predictors of adherence to prophy-
laxis among young people with haemophilia. This is particularly important given the
(apparently) high rate of adherence to prophylaxis in haemophilia, which is much
higher than levels of adherence reported in other chronic conditions.
Therefore, a more exploratory study is required to examine what makes young people
with haemophilia, and the way in which they adhere to their treatment, diﬀerent from
young people with other chronic health conditions. Previous adherence research has high-
lighted that patient perceptions and experiences in relation to their condition, treatment
and support strongly inﬂuence their adherence (DiMatteo, 2004; Horne & Weinman,
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1999; Iannotti et al., 2006; Griva, Myers, & Newman, 2000; Ott, Greening, Palardy, Hol-
derby, & DeBell, 2000). Therefore the present study examines perceptions and lived
experiences in relation to haemophilia and prophylaxis, in order to better understand
of what drives (non-)adherence among young people with severe haemophilia in the
UK. The chosen qualitative approach for this study, Interpretative Phenomenological
Analysis (IPA), combines psychological, interpretative and idiographic components. It
aims to oﬀer insights into how a given person, in a given context, makes sense of a
given phenomenon (Smith, 2010). Therefore its focus is on ‘exploring experience in its
own terms’, without reducing it to ‘predeﬁned or overly abstract categories’ (Smith,
2010). This approach will allow an in-depth investigation of adherence, without forcing
participants merely to reinforce pre-deﬁned ideas and expectations. IPA employs a
‘double hermeneutic’ in which the researcher tries to make sense of the participant
trying to make sense of their experiences (Smith, 2003; Smith, Flowers, & Larkin,
2009). Therefore the study does not require participants to already have clearly deﬁned
ideas about their adherence. In order to make sense of the participant’s personal world
the researcher engages in a process of interpretative activity in which both the participant’s
and the researcher’s own conceptions play an important role.
Methods
Recruitment
IPA studies usually employ a fairly homogenous sample, drawing on the accounts of a small
number of people who have certain experiences in common (Reid, Flowers, & Larkin,
2005). Therefore inclusion criteria for participation in this study were very speciﬁc; partici-
pants had to be aged 12–25 years old, have been diagnosed with severe haemophilia, and
following a prophylactic treatment regimen. Participants were recruited in ﬁve haemo-
philia centres across England and Wales. Initial screening was carried out by haemophilia
doctors and nurses, to identify all participants who met the inclusion criteria. All eligible
patients were approached by a research nurse while they attended routine check-up
appointments. They were given an information sheet about the study to take away, and
encouraged to discuss the study with others. All potential participants (or parents of
those aged 17 or younger) who had taken the information sheet home were then contacted
by a research nurse to check whether they would like to take part. All participants who
agreed to take part were then contacted by the researcher to arrange a date and location
for the interview. Informed written consent was obtained on the day of the interview
from all participants, and in addition from parents of participants aged 17 or younger.
Participants
Participants were 11 males with a mean age of 18.8 years (SD = 5.0), see Table 1 for details.
Interpretative phenomenological analysis (IPA)
IPA is a qualitative research approach that aims to oﬀer insights into how a given person,
in a given context, makes sense of a given phenomenon (Smith, 2010). It is concerned with
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personal perceptions or accounts of experiences, rather than an attempt to produce objec-
tive statements of experiences. The IPA research exercise is a dynamic interpretative
process, where both the participant’s and researcher’s perceptions play an important
role. In this process diﬀerent interpretative stances are possible, combining empathic her-
meneutics (trying to understand what it is like from the participant’s point of view) with
questioning hermeneutics (asking critical questions from the text to interpret people’s
mental and emotional state from what they say).
Yardley’s (2000, 2008) ‘Characteristics of good qualitative research”’ were used as the
guiding principles to ensure this study meets standards in relation to rigour, validity
and credibility. Key considerations in the research process were the transparency of
data presentation, reﬂexivity around the researchers own assumptions, and consideration
of alternative perspectives. After examining themes, and convergence and divergence of
themes, and after immersion in the data, those themes that emerged most strongly
from the interview data and that were relevant to the research questions were reported.
Data collection
IPA studies aim to analyse in detail how individuals perceive and make sense of experi-
ences, and therefore require a ﬂexible approach to data collection. Semi-structured inter-
views are considered a good data collection method for IPA studies, as they facilitate a
more informal and free-ﬂow interview, which enables the researcher to follow cues
from participants and probe areas of interest that appear particularly relevant to each par-
ticipant’s experiences.
A semi-structured discussion guide was developed based on literature in relation to
treatment adherence among young people diagnosed with chronic health conditions
(Alvin, Rey, & Frappier, 1995; Arias Llorente, Bousoño García, & Díaz Martín, 2008; Ian-
notti et al., 2006; La Greca & Bearman, 2002; La Greca et al., 1995; Salema, Elliott, & Gla-
zebrook, 2011; Shaw, 2001), including haemophilia (De Moerloose, Urbancik, Van Den
Berg, & Richards, 2008; du Treil et al., 2007; Duncan et al., 2010; Khair, 2013; Llewellyn
et al., 2003; Thornburg, 2008), and guidance from Smith and Osborn (2003). The draft
discussion guide was then ﬁnalised using feedback collected from focus groups with
patients and haemophilia healthcare professionals (HP). Questions were delivered in an
open-ended and non-directive style to encourage participants to share their story in
their own words. Participants were reassured that information given would be conﬁdential
and not shared with anyone involved with their care.
Table 1. Young people with haemophilia A interview study participant characteristics.
Participant code Ethnicity Age Treatment regimen
1 White British 17 Three times per week
2 White British 24 Activity based
3 White British 21 Twice per week Long-acting
4 White British 12 Three times per week
5 White British 25 Three times per week
6 Asian Pakistani 22 Alternate days
7 White other European 13 Twice per week Long-acting
8 White British 12 Alternate days
9 White British 16 Daily
10 White British 21 Three times per week
11 White British 24 Three times per week
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To build rapport each interview started with some questions about what it is like to live
with haemophilia. To gain insight into their experiences and perceptions in relation to
prophylaxis, participants were invited to describe their treatment regimen, their feelings
about their treatment, potential barriers and facilitators to their adherence, and social
support they receive in relation to their haemophilia and treatment. The order in which
the above subjects were discussed was ﬂexible, and driven by participants themselves.
Interviews lasted between 35 and 95 minutes and were audio recorded, transcribed verba-
tim, and analysed following the Interpretative Phenomenological Analysis (IPA) prin-
ciples and guidelines (Smith, 2003; Smith & Osborn, 2003).
Data analysis
IPA emphasises that the process of discovering themes is based on the researcher being
engaged in a double hermeneutic (Smith et al., 2009), with the aim of making sense of
the participant attempting to make sense of their experiences while recognising that indi-
viduals construct meanings within both a social and personal world.
The transcription of the interview recordings, seen as the ﬁrst phase of analysis in IPA,
consisted of three stages: ﬁrstly an ‘everything audible’ version was produced to ensure
that future transcriptions stemmed from the maximum possible transcribed content. In
the second ‘cleaned and conﬁdentialised’ transcription irrelevant noises and identifying
information were removed. As none of the participants took the opportunity to review
their interview transcript, validation was carried out by an independent researcher who
read the transcripts while listening to the recordings. The main researcher then re-read
the transcripts to ensure that all identifying information was removed, and the transcripts
were ready for analysis.
The analysis process started by making comments and annotations (in NVivo) while
reading and re-reading the transcript. The researcher then coded the transcript while
re-reading the transcript along with the comments and annotations. The coded transcript
was then reviewed, and the coding was reﬁned where needed. The NVivo coded transcript
was then exported, creating an Excel spreadsheet with one line for each code, and columns
providing more information about the code (code name, frequency the code was used
during coding, example quote, and notes/reﬂections including bracketing oﬀ personal
interpretations that may inﬂuence the analytical process, as well as themes to which the
code may belong. The themes were then reviewed to identify overarching themes,
which were reported in an additional column. Throughout this process the researcher con-
tinually returned to the transcripts to ensure that the superordinate themes still reﬂected
what participants had actually said. Finally, the overarching themes were reﬁned and pre-
sented in a table together with each of their subordinate themes. As recommended by
Smith and Osborn (2003), it was decided to ﬁrstly conduct IPA on a single interview in
its entirety. The remainder of the transcripts were then taken through the analytical
process together. To ensure rigour, validity and credibility, an independent researcher,
who did not have any prior knowledge of haemophilia or treatment adherence, then
reviewed the subordinate and superordinate themes, and the way they related to the
initial transcripts and each other. Questions raised during this process highlighted areas
that needed speciﬁc attention in the write-up of results to ensure clear and transparent
reporting of the results.
282 S. VAN OS ET AL.
Ethics statement
Ethical approval was obtained from the NHS National Research Ethics Service Committee,
London – City Road & Hampstead (NRES, Ref: 12/LO/2030).
Results
Superordinate and subordinate themes
Participants’ accounts clustered around four superordinate themes, which are shown in
Table 2 together with their related subordinate themes. The table also shows for which
participants each of the subordinate themes was relevant.
Theme 1: Balance between good self-management and living the life you want
This theme encapsulates the impact haemophilia has on day-to-day life. Often diagnosed
at a young age, haemophilia is not only a lifelong health condition, it is part of who
patients are and the way they live their lives. Participants described how they were
often in and out of hospital as children, resulting in school absence, which for some
had a negative eﬀect on academic and professional opportunities. They also described
how they had missed out on social occasions and opportunities to make friends because
they were often excluded from activities that were deemed too risky (such as playing foot-
ball). The young people involved in this study vocalised a strong desire to live a ‘normal’
life, and rely on their prophylactic treatment to oﬀer them the protection they need to
pursue and achieve life goals, and engage in activities they enjoy. In recent years the
focus in haemophilia care in the UK has been moving towards a more individualised
Table 2. Young people with haemophilia interview study superordinate and subordinate themes for
each participant.
Superordinate Subordinate themes
Participants
1 2 3 4 5 6 7 8 9 10 11
1. Balance between good self-
management and living the
life you want
1.1 Haemophilia, bleeds and pain
are part of life and who I am.
x x x x x x x x x x
1.2 Avoiding risk is key x x x x x x x
1.3 Patient is haemophilia expert x x x x x x x x
1.4 I tailor my treatment around my
lifestyle.
x x x x x x x x
2. Perceptions, barriers and
facilitators.
2.1 Barriers to adherence. x x x x x x
2.2 Haemophilia and treatment
related anxiety.
x x x x x x x x x x x
2.3 Non-adherence is usually due to
forgetting
x x x x x x x x x x x
2.4 Taking treatment is
inconvenient and no fun.
x x x x x x x x
2.5 Taking treatment is part of my
routine.
x x x x x x x x x x x
2.6 Treatment protects me so I can
live a normal life.
x x x x x x x
3. Support from family, friends
and the haemophilia centre
keeps me on track.
3.1 Support from mum and dad is
key.
x x x x x x x
3.2 Social and peer support. x x x x x x x
3.3 The staﬀ at the haemophilia
centre encourage me to keep to
my treatment regimen.
x x x x x x x x x
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approach (Richards et al., 2010). This means that in many cases haemophilia teams agree a
treatment regimen that is tailored to the individual patient, based not only on clinical con-
siderations such as bleeding phenotype (individual tendency to bleed) and pharmacoki-
netics (the movement of a drug into, through, and out of the body), but also the
patient’s lifestyle and physical activities (Ar Muhlis, Vaide, Berntorp, & Björkman,
2014; Gringeri, Doralt, Valentino, Crea, & Reininger, 2016).
Subtheme 1.1: Haemophilia, bleeds and pain are part of life and who I am. As haemo-
philia is usually diagnosed in the ﬁrst few years of life, patients have always lived with the
condition and it is therefore part of their identity.
I just kind of accept it as a part of who I am and what I’ve got. (P.1, 17 years old)
Most participants appeared to accept haemophilia-related issues (e.g. bleeds, pain, and
joint damage) as part of their life. They tend to take a ‘you just have to get on with it’
approach, and do not dwell on these issues.
It’s okay, the only thing I’m really worried about is when I have to inject myself but then I
think that everyone with haemophilia has to do it. (P.8, 12 years old)
Subtheme 1.2: Avoiding risk is key. It can be challenging to strike a balance between living a
normal life while avoiding situations that increase the risk of bleeding. However, it seems
that there are many different interpretations of what ‘avoiding risk’ is, and how this inﬂu-
ences the way you live your life. Different families and individuals deal with haemophilia
in different ways, and perceive the potential risks associated with activities differently.
However, managing risk is an important part of life for all young people involved in
this study. For some, this means that as long as they have taken treatment, they feel pro-
tected while they get on with the life they want to live.
If I am doing anything active obviously I would have always had my medication uhm. I don’t
really leave anything to chance. Uhm so as long as I’ve had that then there is not a huge panic
uhm but obviously if I have broken a bone then you’re gonna have to go to hospital either
way uhm. (P.2, 24 years old)
For others managing risk has a more central role in their lives, where each activity is risk
assessed, and where limitations to what they are able to do are an important consideration
in everyday life.
But knowing my limitations is deﬁnitely, ah, a very important part of having haemophilia, cos
if you go past what you’re limited to be able to do, then you are gonna cause more damage.
(P.1, 17 years old)
In particular, participants who live an active lifestyle feel that taking treatment in prep-
aration of activities is crucial in reducing the risk of activity-related bleeds. This means that
they often tailor their treatment by taking top-ups in addition to their regular prophylaxis,
to ensure they are covered while being physically active.
Recently I’ve done a 10k run and I knew that the week before I’m training for it, make sure
you’ve given yourself plenty of factor, maybe increase the dosage a little because you’ve got a
big run coming ahead and if something were to happen or generally you’re going to ache after
the run anyway so it would be good to have that factor in your system and a good healthy
amount in that week before to get you prepared. So if I did miss something, which I
didn’t, I would have been worried just in case something happens or I get a cut or something
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or I bang my head or something and you keep on bleeding and bleeding, whereas if you were
prepared then you wouldn’t bleed as much. (P.10, 21 years old)
It is interesting that patients’ perceptions of advice from their haemophilia centre
diﬀers widely, with some suggesting that they feel that they are strongly discouraged
from getting involved with sports, whereas others feel that they are encouraged to be
active and ﬁt. This could be because diﬀerent haemophilia centres give diﬀerent advice,
but could also be due to diﬀerent interpretations of the same advice. This suggests that
healthcare professionals (HP) need to consider carefully how the advice they give is under-
stood and implemented. Particularly as individual circumstances, family dynamics and
personalities will inﬂuence the way in which patients and their families take on advice.
I think there’s a couple of haemophilia centres who aren’t handing out, just aren’t really
handing out treatment. They’re just saying don’t do sport, if you continue to do it we
don’t give you the treatment. Which is a shame to hear because I know all the centres <in
this area> encourage sport and an active lifestyle. And you know I’ve learned since I was
swimming at a high level that’s when all my problems stopped. That coupled with the medi-
cation. It’s been super ﬁt, super healthy, treating the haemophilia with a bit of respect. (P.2, 24
years old)
As illustrated above feedback from several participants in this study suggests that being
ﬁt, healthy and strong helps to manage haemophilia and reduces bleeding. Many haemo-
philia centres advise their patients to take up swimming as it is a non-weight bearing
activity that can help patients to stay ﬁt and strong without risk of injury. Several partici-
pants in this study mentioned that they swim regularly, or are intending to take up swim-
ming in the near future.
If I could play football like you run around for like ninety minutes, that could aﬀect me like
the next day because I could have sore ankles, because swimming’s not weight-bearing it’s
ideal. (P.11, 24 years old)
Subtheme 1.3: Patient is haemophilia expert. In particular, participants aged 18 and
older described how they feel that they are experts in haemophilia. They have learned
how to recognise the symptoms of a bleed, they know what kind of activities increase
the risk of bleeding, how to tailor their treatment in preparation of physical activity,
and they know how to treat themselves if a bleed does occur.
I think, I’m also haematologist [laughs] because I had so much experience of these things but
obviously I feel I had to teach myself, I’ve improved myself a lot and I’ve gained enough conﬁ-
dence too. (P.11, 24 years old)
As haemophilia is a rare condition, several participants described situations in which
(non-haemophilia) HPs did not know how to deal with their condition, or gave them
incorrect advice (e.g. some were prescribed nonsteroidal anti-inﬂammatory drugs,
which can worsen bleeding problems). For some participants, these experiences encour-
aged them to become more self-suﬃcient. Even those participants who did not describe
themselves as experts appeared very conﬁdent about their abilities to manage their haemo-
philia, and were knowledgeable about the way factor replacement treatment works.
Cos there’s nothing high-risk about sleeping. The only time I’ll take it in the evening is if I’ve
had like 2000 units on a Monday and then I am doing something active on the Tuesday
evening then I’ll maybe have a top-up of a 1000 that evening. (P.2, 24 years old)
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Subtheme 1.4: I tailor my treatment around my lifestyle. In recent years the focus in haemo-
philia care has been moving towards a more individualised approach, where patients are
encouraged to tailor their treatment around their lifestyle. So instead of the standard 3 injec-
tions per week (usually on Monday, Wednesday and Friday in the morning), patients may
tailor the treatment frequency and dosing around their activities and lifestyle. Many
patients also take additional treatments (top-ups) to cover themselves for ad-hoc activities
on days that fall outside of their usual prophylactic regimen. Themajority of participants in
this study tend to tailor their treatment using top-ups. However, two participants described
more ﬂexible regimens that they tailor on a daily basis around their very active lifestyles.
I can have some pretty intense weeks. Where I maybe go over, uhm not my quota because
there is not really a quota for it, but kind of if I’ve taken it every day and I’ve had couple
of days where I’ve gone 1000 and 2000. If I have a day or a few days where I am not
really active then I sort of try and knock it back quite a bit. (P.2, 24 years old)
Theme 2: Perceptions, barriers and facilitators
This theme encapsulates barriers to adherence as described by the participants in this
study, and may therefore not include all possible barriers to adherence to prophylaxis
that young people may experience.
Subtheme 2.1: Barriers to adherence. Most young people involved in this study have a
busy lifestyle, which can make it hard to ﬁt treatment in. Many leave home early in the
morning to get to school or work, and ﬁt in social and physical activities before they
return home in the evening. Most participants mentioned that they have to get up a
little earlier to take their treatment and that when they are particularly busy they do some-
times forget.
In the morning I’m normally in a rush. So that’s when I normally tend to have it, so that’s
why I tend to forget. I struggle to keep track of the days as well. (P.3, 21 years old)
Next to forgetting, one of the main barriers for the participants in this study is the intra-
venous injection itself, as it is not pleasant to have to inject regularly. And although par-
ticipants did not describe any issues around needle phobia, it appears quite common for
patients to experience some issues around venepuncture or venous access. Not being able
to ﬁnd or access a vein can be frustrating, painful and can sometimes cause anxiety. Some
patients described how they tend to give up on their injection if it doesn’t work the ﬁrst or
second time, and come back to it later in the day or even the following day.
Sometimes when you put the needle in, sometimes it can be quite diﬃcult. Cos you can’t
always don’t always ﬁnd the eh ﬁnd the ehm the vein. Don’t always ﬁnd it. (P.4, 12 years old)
Once they have found one or two injection sites that work well, most patients tend to stick
to those sites for all their injections. This makes it easier and less painful, particularly as the
sites become less sensitive due to the scar tissue that results from frequent injections.
I could obviously just go into another vein. But that would just be going into tender skin then.
(P.3, 21 years old)
Sometimes there are practical reasons why patients struggle to take their treatment. For
instance, they may not be able to inject themselves because of an injury to their arm. In
emergencies patients may not always be able to mix up or take treatment themselves.
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The design of the treatment, and the way it is mixed up in preparation for the injection,
can make it challenging for inexperienced people to help. This makes emergencies more
stressful, and may increase general anxiety about managing life with haemophilia. One
participant described an experience during a ‘lads holiday’, which has made him more
anxious and risk averse about going away with friends or attending parties that may
involve alcohol and young people having fun.
‘I’m going to have to go back to the room to treat myself, can one of you come and help me?’
my mates oﬀered and we went back. It was hard for me to do it because it was bleeding, so I
had to describe to my friend how to make the bottle up to get the injection ready. Obviously I
don’t expect my friend to inject me. But I thought if you make it up for me I could put this
extra pressure on and give myself a bit more time to make it stop. So when I come to inject
and go like that then the blood will be minimal compared to if I just make it and the blood
ﬂow is going down. So I was telling him but it was slightly complicated. For me it’s second
nature, but obviously for him I was just… trying to take it on board what I was giving to him.
But if it was just maybe an easier way of making it or less compartments. Sort of readymade
so all you have to do is inject then it would be like simpler. I could have just got on with it.
(P.10, 21 years old)
Because prophylactic treatment involves an intravenous injection, it is important to
ﬁnd a private and clean place to do their treatment. This can be challenging when on
holiday, or out and about.
I’ve never had factor on a plane before, and then we get in the airport and it’s hustle and
bustle, you can’t really pull the lads to one side say “I’ve got to go to the toilet and do it”,
so ‘I’m not really going to have treatment here until I get home’. So it was just the fact
that I couldn’t have any, that was more the worry. It made me feel a bit not organised,
not good about myself. (P.10, 21 years old)
Subtheme 2.2: Haemophilia and treatment-related anxiety.As described above, anxiety can
make the intravenous injections more challenging, particularly for patients who have
venous access or venepuncture issues.
What makes treatment diﬃcult is if I’m in – If I’m stressed. If I had a stressful day and I’m
doing it in the evening it’s diﬃcult to locate veins. Because they tend to shy [laughs] away
from you. If I’m in a bad mood they shy away. I – it’s always very mood speciﬁc. If I’m
quite relaxed and n a good mood then I can easily see them on the surface and it’s easy to
get in there. (P.1, 17 years old)
Although haemophilia teams work with patients from a young age to support and
encourage them to take over responsibility for their injections gradually, younger partici-
pants who were not doing their own injections yet appeared a little anxious about the idea
of taking over their own injections.
I have to one day obviously but it’s a bit scary, but I do have to eventually. (P.8, 12 years old)
The majority of participants explained that doing their own injections was diﬃcult to
start with, but became easier with time and experience. None of the participants appear to
have developed needle phobia, although there was some indication that some of themmay
not have been completely at ease with their treatment. Several participants explained that
they would never take their treatment in front of someone else, or would only do it in front
of people they are familiar with.
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Generally I’ll always do it before I go out or work is okay because you’re familiar with work
so, I don’t like doing it in front of like, I don’t mind doing it in front of but, you know, people
that don’t know about it and don’t know what it is, that’s, so generally I always make sure I
have it in a safe place at home, have it at work, have it at a friend’s house… . (P.10, 21 years
old)
Not wanting to take treatment in front of others indicates that there is some anxiety about
how others respond to the injection, and possibly some concern about stigma. Some par-
ticipants described how reactions from work colleagues and potential partners can be
upsetting or cause insecurity.
Whereas some girls maybe I’ve seen in the past they’re like ‘what is it? What is it? You have to
inject yourself’, you know, ‘I don’t understand why’ and makes you look a bit like, you know,
it shows you up, makes you feel like, you know, I’mnot good enough because I’ve got to inject
myself or because it looks bad and as soon, normally generally the girls, I explained to them
and said ‘look this is what it is, this is what I have to do’ and they’re ﬁne. (P. 10, 21 years old)
It is clear that even for patients who have supportive families and friends around them,
haemophilia can cause anxiety at times, particularly in cases where a bleeding episode
causes them to miss school, work or social occasions. Although many patients described
a certain level of pragmatism and not wanting to dwell on issues (see above), for some,
particularly younger patients, haemophilia-related issues can become overwhelming at
times.
Like if I have a bleed and I’m resting, I sometimes go on the Xbox and just like play and kind
of forget about like the bleed. (P.8, 12 years old)
Some described how they would ‘ﬂee’ from their haemophilia for a while by becoming
absorbed in a ﬁlm or computer game, others engaged in more active coping mechanisms
like speaking to friends or seeking psychological support to help them deal with issues
related to their haemophilia.
I do have counselling as well. And it all must stem back to when it all started or whenever.
That’s just another problem I think. Just for someone to talk to, it is helpful. But I don’t like to
– I don’t like to talk about a lot of things. I keep a lot to myself, so that’s why I go there. So
yeah, haemophilia does cause a few problems in that way. Yes, it’s all about that, obviously
growing up with it. (P.3, 21 years old)
Some participants were able to access psychological support through their haemophilia
centre directly, or through referral to a psychological support service provided by the hos-
pital or local NHS trust. However, long waiting lists or diﬃculty in accessing support
meant that some participants sought a private counsellor or therapist. Regardless of
how they accessed the support, participants felt it was very helpful to discuss their haemo-
philia-related issues with someone outside of their family, social circle or haemophilia
team. Several participants made unprompted suggestions that it would be helpful if
support was easier to access. They felt that in an ideal world psychological help would
be available through haemophilia centres, so that patients could receive support without
delay and without incurring costs. Support from family, peers, friends and the haemo-
philia team will be addressed in more detail below under theme 3.
Subtheme 2.3: Non-adherence is usually due to forgetting. Despite the treatment being
quite unpleasant, self-reported adherence among participants in this study was high.
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Very few participants admitted to deliberately skipping treatments, and those participants
who did would usually only skip a treatment if they were expecting to have a very inactive
day. As described above, these circumstances are not necessarily considered as non-adher-
ent for those participants who have agreed a more tailored treatment regimen with their
consultant.
We do sometimes just not bother with the treatment, if I’m not going to be doing anything
that day. (P.9, 16 years old)
None of the participants felt that adherence was an issue for them, and most were
motivated to keep to their treatment regimen although some admitted to sometimes for-
getting treatments, due to their busy lifestyle or being distracted by other priorities.
… over really important stuﬀ it’s no, I don’t miss it. But I’ve had the odd kind of day where
I’ve gone uhm. Where I’ve had an active day and I’ve got halfway through it and bugger it, I
didn’t take my medication. So I’ll either go home and take it or if I just be super careful then
… So I think you know maybe we’re talking twice a year I make a mistake with it. (P.2, 24
years old)
Yeah, I occasionally do forget it… if I have forgotten during the day mum would say have
you done it? If not, right, you do it tomorrow morning then. (P.4, 12 years old)
Most participants take their treatment as soon as they realise they have forgotten it,
others wait until the next morning. There were two participants who, despite reporting
high adherence, described situations where they may miss two, three or even four injec-
tions in a row. It was not clear what the actual level of adherence of these participants
was, and the language they used indicated that perhaps they were a little confused
about this themselves.
No I – I won’t deliberately miss two three or four in a row, and if – if – the problem is if I forget
one – the little dull aches a bit, yeah ok, if I miss two then they get worse, then it – then that’s it.
Because you realise, yeah I’ve missed two, I need to get it done. And even if it’s a day when I’m
not treating, I’ll treat myself for it. Because I can’t get these bruises. (P.1, 17 years old)
Some participants described being quite anxious or worried about the risk, when they
realise they have forgotten their treatment. They clearly feel that their treatment protects
them, and feel vulnerable when they realise they are not covered. For these participants,
this anxiety could also act as an extra motivator to adhere, as it appeared that these par-
ticipants forget very rarely.
… for me it’s a really horrible feeling to be doing something active having not had my medi-
cation, because then you know you’re vulnerable. (P.2, 24 years old)
One participant in particular described how forgetting treatment aﬀects his mood, and
makes him feel disappointed in himself. He feels happy when he has had his treatment, as
he knows he is protected. But when he has forgotten his treatment he feels exposed and
anxious.
A bit like exposed, feel a bit like, you know, a bit disappointed in myself in a way, sort of a bit
like I should have had some before and I feel a bit like anxious to get it done really and I go in
a bit of a bad mood or I go a bit, you know, feel a bit uncomfortable and not as happy as
usually would be. (P.10, 21 years old)
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Subtheme 2.4: Taking treatment is inconvenient and no fun. It is very clear that none of the
participants enjoy taking their treatment, and would much prefer not to have to take it.
Many participants mentioned that they do not like having to inject themselves intrave-
nously, and would much prefer to take a tablet or subcutaneous injection.
Like instead of doing the injection you just gotta take a tablet. I know that you can’t do that
but… . (P.4, 12 years old)
… like I wish it could be like a diabetic who gets it in a pen? (P.11, 24 years old)
One of the most frequently mentioned issues around the treatment was that it can be
quite time-consuming. As most patients take their treatment in the morning it can be
diﬃcult to ﬁt it in, and some participants admitted to sometimes having to miss breakfast
when treatment takes a bit longer than usual, or when they do not have time for both treat-
ment and breakfast.
The prophylaxis only really takes about 20 minutes but I don’t really have time for breakfast
afterwards so it’s quite irritating before school but most of the time it’s not too bad. (P.9, 16
years old)
Interestingly, there was one participant who really disliked having to mix the treatment.
He was not concerned about the injection itself, but felt mixing up treatment is boring and
tedious and resented having to do it before every injection. He explained that his parents
would often mix his treatment for him when he was growing up.
Especially when you’re growing up sometimes, like once a week for someone to mix it for you
so you ain’t got to worry about it, it’s just ‘here you are, I’ve done it’, ain’t giving it, it’s just
mixing it, especially when there was a lot of it, it was really tedious. (P.11, 24 years old)
Subtheme 2.5: Taking treatment is part of my routine. Although many participants
admitted that they dislike their treatment, they also appeared to have accepted it as part
of their life and have ﬁtted it in their routine. For most, it has become just another
thing they need to do before they leave home in the morning.
… it’s become second nature. It’s an easy thing to do now. I get up early in the morning and I
sit – sat at the breakfast bar in there and I just sit and do it. I don’t even give it a second
thought, you put it together and inject. (P.1, 17 years old)
It’s uhm it’s just something that’s gotta be done. It’s like it’s like having a shower in the
morning. That’s pretty much the long and short of it. (P.2, 24 years old)
Participants described how the injections were often diﬃcult and painful when they
were younger, particularly when they were learning how to do the injection themselves.
But by the time they reach young adulthood they tend to be very skilled, and able to
inject themselves without any issues.
Yeah, I can do it with my eyes closed I reckon [both laugh] if I had to I think I could. (P.5, 25
years old)
In recent years factor replacement treatment has improved signiﬁcantly, which has
made it much easier for patients to keep to their regimen. Key improvements highlighted
by participants in this study include the reduction in volume (making it easier to mix up
and requiring smaller syringes); easier to store and transport (it does not require
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refrigeration and the boxes are smaller) and the improved instructions on the packaging
(particularly helpful in emergencies when other people may need to help).
None of the participants suggested that these improvements have had a direct positive
inﬂuence on their adherence, particularly as their adherence was generally already quite
high. However, they felt that taking their treatment has become a lot easier and less
time-consuming, which in turn may reduce negative associations with treatment and
therefore reduce the risk of patients skipping treatments.
It’s a lot smaller now, so it’s a lot easier. You haven’t got to take these massive bottles which
takes hours to mix up. It’s all very easy, you squirt in, you squirt out, and it’s all very quick
these days (P.5, 25 years old).
It used to it had to be kept like fridge cold. But now it’s more just under more like room temp-
erature which is ﬁne. Which makes life quite easy (P.2, 24 years old).
As described above, non-adherence in this patient group tends to be due to forgetting.
Many participants described easy and practical solutions that help them to remember their
treatment, such as visual reminders (e.g. putting the bright yellow sharps bin on the break-
fast bar); linking treatment to particular activities (such as having breakfast); and digital
reminders (alerts on a mobile phone, tablet or computer).
It appeared that they were keen to ﬁnd their own solutions and ways of managing
their treatment, as everyone is diﬀerent and has their own challenges to overcome. For
instance, while some were keen to use their smartphones for reminders, another par-
ticipant explained that he would never trust a digital device alone without a back-up
reminder.
So it would make a noise or whatever, so you’d know it was that day. But that’s just then trust-
ing a device to tell you when to do it without thinking… . (P.3, 21 years old)
Despite the various reminders, and the motivation to keep to their regimen, some par-
ticipants admitted that they do occasionally forget their treatment. This is often because
they live busy lives, and are sometimes distracted by other priorities. However, they
tend to have some treatment stored at work or school so that they can take it there in
case they have forgotten it at home. Having some treatment stored at work or school pro-
vides an extra safety net, which seemed particularly important for those participants who
do not want to take any risks.
… but I’ve also got some at work. You know, just in case I need it. Like in an emergency,
which I’ve had to before. Or just in case I forgot to take some with me, so there’s always
some there. (P.3, 21 years old)
Subtheme 2.6: Treatment protects me so I can live a normal life. Many participants
explained that they feel their prophylaxis protects them, and allows them to live a
normal life. For some that means that they feel protected in everyday activities, such as
going to school or work. Others feel that prophylaxis supports them in living an active life-
style, including competing in top-level sports.
It’s helping me lead a normal life. (P.2, 24 years old)
The treatment works quite well, it stops most bleeds. It’s only the serious ones that get
through now. We do a big dose before and after the activity… I’ll still get a small bleed
but nothing like as bad as I would get if we didn’t. (P.9, 16 years old)
HEALTH PSYCHOLOGY AND BEHAVIORAL MEDICINE 291
Participants explained that they top-up to cover themselves for sport and physical
activities. Most seemed to recognise that in addition to reducing the risk of bleeds, prophy-
laxis helps to prevent long-term issues such as joint damage.
If I don’t take my medication I’ll start getting internal bleeds that’s going to aﬀect me later in
life with joint damage and what not. (P.2, 24 years old)
Theme 3: Support from family, friends and the haemophilia centre keeps me on
track
Self-management for haemophilia includes a number of behaviours, some of which can be
quite challenging. The majority of participants felt that they would not be able to look after
themselves without support from their parents and the staﬀ at the haemophilia centre.
This theme covers all the forms of support that were described by participants.
Subtheme 3.1: Support from mum and dad is key. Parental support is particularly
important in relation to adherence. As described above, in the majority of families it is
the parents who are responsible for their child’s haemophilia treatment for the ﬁrst 12
years or so. This means they have to inject their child several times each week, log each
treatment, arrange for treatment to be delivered, arrange regular hospital check-up
appointments, and be on stand-by just in case their child experiences a bleed at school.
I think they was always worried and mum would come into school every now and then to
give me treatment and things if I needed, if I fell over in the playground or, you know,
when I was younger they’d come in and they’d say, you know ‘I’m here, we need to do
this, we need to do that’. (P.10, 21 years old)
Parental support appears particularly important in encouraging adherence, as parents
tend to remind their child to take his treatment every time it is due. Some parents continue
to remind their child even after they has left home; this appears to be a habit of a lifetime
that is diﬃcult to break. Many parents also continue to do the actual injection every now
and then, just to share the burden and make life a little easier. Parents often also stay
involved with arranging the deliveries of treatment, and continue to help when bleeds
or other health issues occur.
Now that I am a bit older I am quite self-suﬃcient with it, but uhm cos I travel a fair bit so my
mum looks after, the treatment gets delivered to my mums house rather than mine, cos mum
is in a lot more often than I am. She’ll keep an eye on my stock I’ve got. Uhm so, yeah they are
still. Yeah everyone supports me really nicely. (P.2, 24 years old)
Subtheme 3.2: Social and peer support. In addition to support from parents and siblings,
participants described supportive social networks they could rely on for practical and
emotional support.
And especially with the friends who I’ve been on holiday with they understand it a lot better
because I understand their problems, they understand my problem, we know what our limit-
ations are – and we can just stick together. (P.1, 17 years old)
However, as described above, some participants felt that they had missed out on oppor-
tunities to develop social skills due to their haemophilia. Some reported that they therefore
found it diﬃcult to develop supportive relationships and struggled to ask for or receive
social support. These participants generally continued to obtain their support from
within the family (speciﬁcally parents).
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Advice about what activities children with haemophilia should avoid has changed in
recent years, and many children are now allowed to take part in physical education
lessons at school as long as they avoid contact sports such as rugby and hockey (Farrugia,
Gringeri, & von Mackensen, 2018; Howell, Scott, & Patel, 2017). Any activities that may
cause head injury need to be avoided at all costs, as intracranial bleeding represents one of
the biggest risks. However, it is unlikely that young children who are growing up with hae-
mophilia today are excluded from playing outside at break time at school. Hopefully, this
means that this new generation is able to take part in most activities at school, and does not
miss socially. This in turn may help them develop social skills and form supportive friend-
ships. This certainly appeared to be the case for the younger participants in this study, who
described very supportive friendships.
It doesn’t really bother me that much now because most of my friends at school help me. It
feels all right because most of my friends know about it and they to talk to me about it. (P.8,
12 years old)
Sometimes when I’m at school I do talk about it or like if I say I’m in pain they normally help
me and take me to a teacher. (P.4, 12 years old)
One form of social support that may be particularly helpful is peer support from other
young people with haemophilia (Omura et al., 2013). As it is so rare, patients do not often
meet other people who have haemophilia (Khair & Holland, 2013). One participant joked
that he always felt that he was the only person with haemophilia. Now that he is in his
twenties he receives psychological support from a counsellor to talk about his haemophilia
and the way it has aﬀected him. Some haemophilia centres have peer support groups, and
organise social outings to give young people with haemophilia (YPH) the opportunity to
meet and socialise. Pressure on budgets make it hard to keep these activities going, and in
some centres they have now stopped. Participants indicated that they had beneﬁtted from
opportunities to interact with other YPH outside the hospital setting.
Subtheme 3.3: The staﬀ at the haemophilia centre encourage me to keep to my treatment
regimen. The majority of patients appear to have a good relationship and regular contact
with their haemophilia centres. Sometimes this is just informal contact to check how
patients are doing, and other times it may be to provide support for speciﬁc issues. It
appears that HP in the centres involved in this research study are able to recognise
when particular individuals need help or additional support.
Yeah, it’s nice to know, they ring up and ask and they’re concerned and, you can, obviously it
was a mistake on my behalf so I said like no, and they told me how to do it properly and
generally it was, the nurses are good I think, yeah, they’re okay. They help out as much as
they can and it was good that they’re keeping an eye on me really. (P.10, 21 years old)
Nurses appear to keep a close eye on patients, particularly those who suﬀer from regular
bleeds. They check Haemtrack (a secure online treatment log that enables patients to
record all therapies as they occur, and allows clinicians to see up-to-date information to
help monitor, optimise and improve patient care) to monitor individual patients. In
many cases where a review of Haemtrack reveals that a patient may not be adhering to
their treatment regimen, or has had a serious bleed without contacting the centre,
nurses contact the patient to discuss potential issues. This appears to encourage patients
to adhere to their prophylaxis, and stay on top of managing any bleeds.
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Generally the nurse will ring and say ‘you’ve had a lot of factor, we’re looking on your
Haemtrack, you’ve had a lot’, I think one time they’d mistaken, I had this ankle injury
but I kept putting it was a follow-up bleed, because it was the same sort of bleed reoccurring
again, but in fact I should have done new bleeds every times, so it looked like I’d had this
bleed for like nine hundred hours or something. So then they rang up and was like ‘look, is
this bleed this bad or is it because it’s reoccurring but is it because it’s a new bleed?’. (P.10,
21 years old)
It appears that many haemophilia centres use the carrot and stick approach, where they
combine regular encouragement and support with a telling oﬀ when patients are not
adhering to their treatment.
I know deﬁnitely you do get the same motivation when every time I go for the clinic appoint-
ments, trust me, I do get a big lecture! (P.6, 22 years old)
Regardless of how the different haemophilia centres approach different patients, all par-
ticipants in this study were very positive about the healthcare and support they receive.
It is clear that many nurses, haematologists, psychologists, physiotherapists and other
allied health professionals often go out of their way to support their patients.
Support from the centre makes me feel less alone. (P.3, 21 years old)
The nice thing for me is I know they’re there if I need them. (P.2, 24 years old)
Support from family, friends and haemophilia team helps young people to keep on
track with their treatment. Parents appear to be very involved with their sons’ haemophilia
management, even after they leave home. Help and support from the haemophilia team
appears an important facilitator to adherence.
Discussion
The present study examined adherence to prophylaxis in interviews with 11 young
people with haemophilia, recruited from 5 haemophilia centres across England and
Wales.
The ﬁndings suggest that many young patients experience a tension between their
desire to be ‘normal’ and the successful self-management of their haemophilia. Self-
reported adherence to prophylaxis was good, with few participants admitting to intention-
ally skipping injections although forgetting was sometimes reported. However, the
ﬁndings also indicate that due to the increasingly personalised and ﬂexible approach to
prophylaxis, adherence is not always straightforward to deﬁne. Several participants
appeared slightly confused when describing their own levels of adherence, particularly
when they were asked to distinguish between forgetting and skipping.
The main barriers to adherence are the time and eﬀort needed to take treatment (ﬁtting
this into an already busy lifestyle); dislike of the intravenous injection; venous access
issues; anxiety or stress (haemophilia-related as well as general); and being out of the
normal routine (e.g. on holiday)(Schrijvers et al., 2013; van Os et al., 2017).
Support from family, friends and haemophilia team helps young people to keep on
track with their treatment. Parents appear to be very involved with their sons’ haemophilia
management, even after they leave home. Help and support from the haemophilia team
appears an important facilitator to adherence.
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Strengths and limitations
Data represent the lived experience of individual participants. Existing quantitative
measures do not permit the study of adherence to prophylaxis in an increasingly person-
alised treatment approach. It was crucial, therefore, to examine this issue using a qualitat-
ive approach in order to determine how adherence is experienced in relation to the
everyday lives of patients, ﬁtting around roles, identities, lifestyles and relationships.
The use of IPA to analyse interviews was especially important since it does not rely on
measuring previously formed attitudes of which participants are consciously aware but,
instead, involves the researcher making sense of participants making sense of their
experiences.
One potential limitation is that the participants were not necessarily representative of
the whole population of young people with haemophilia. It is possible that those who
agreed to be interviewed are more motivated and engaged in relation to their treatment.
Those who are non-adherent or disengaged are less likely to take part in research about
adherence. Nevertheless, participants were recruited from ﬁve haemophilia centres
across England and Wales, including paediatric, adult, and mixed centres. These centres
are very diﬀerent, not only in terms of their geographic location, but also their organis-
ational structures. This allowed the researcher to gain insights into experiences across a
range of treatment contexts.
The focus in this study is speciﬁcally on young people rather than including patients of
all age groups. It is important to focus on one age-group because there are age-speciﬁc
issues that may inﬂuence adherence, such as historical changes in types of treatment avail-
able (e.g. most young people with haemophilia alive today have followed a prophylactic
regimen from childhood compared to older patients who did not have this treatment avail-
able when they were young), and factors associated with diﬀerent developmental and life
stages. Research using a diﬀerent age-group may therefore identify diﬀerent issues inﬂuen-
cing adherence.
A ﬁnal limitation is that the majority of interviews took place within hospitals.
Although the interviews were conducted by a psychologist who was not involved in par-
ticipants’ haemophilia treatment, and in a private room, patients’ responses may have
been inﬂuenced by their previous (potentially stressful or traumatic) experiences in the
hospital.
Implications
Notwithstanding the limitations discussed above, the ﬁndings of this study have a number
of implications. The results indicate that adherence among young people is generally good,
particularly in comparison to adherence among young people diagnosed with chronic
health conditions (DiMatteo, 2004; KyngÄs, Kroll, & Duﬀy, 2000), such as diabetes (Ian-
notti et al., 2006; Griva et al., 2000; La Greca et al., 1995), juvenile arthritis (Salema et al.,
2011), and asthma (McQuaid, Kopel, Klein, & Fritz, 2003). Support from parents and the
haemophilia team appear to be the most important facilitators to their adherence. Haemo-
philia teams appear to work hard to maintain a good relationship with patients, particu-
larly with those patients who are struggling. In the current economic climate, and in the
context of reorganisation and rationalisation of the NHS, this model of care may come
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under increased pressure and may not be able continue if resources are cut. However, the
ﬁndings from this study provide evidence for the beneﬁts of the current approach in
managing patients with severe haemophilia, and may therefore help haemophilia
centres to build a case to retain their current level of resource.
Many patients require, and indeed access, additional support from a psychologist to
help them with the psychological and social impact of haemophilia. This psychological
support appears to be an important element of the comprehensive care that many patients
require (‘Feeling angry? Frustrated? Anxious? Low?,’). Participants felt that this support
should ideally be provided within the haemophilia centre, so that the threshold to
access this support is low and psychologists are able to work with patients pro-actively
to address issues before they escalate. However, several of the centres involved in this
research no longer have (or never had) a psychologist embedded in their team. The
ﬁndings of this research may help centres to put forward an argument to improve
access to psychological support, or indeed appoint a psychologist in their centre.
The ﬁndings also indicate that, due to the increasingly ﬂexible approach to haemophilia
treatment in the UK, adherence to prophylaxis is diﬃcult to deﬁne and assess. Patients’
tendency to bleed is not only determined by the severity of their haemophilia and
extent to which they adhere to their treatment, but also by their bleeding phenotype,
which can be relatively mild even for patients with severe haemophilia. Therefore it
could be that a patient with severe haemophilia ‘gets away’ with non-adherence to a
certain extent, and may not necessarily need to improve their adherence. The ﬁndings
of this research suggest that it may be useful to shift the focus of future research away
from looking for ways to improve adherence generally, but rather to focus on improving
adherence among those patients who are likely to have worse outcomes due to sub-optimal
adherence.
In a quantitative study (van Os et al., 2017) non-adherence was more likely to be due to
forgetting than skipping. Although it is likely that young people’s busy lifestyles are par-
tially responsible for this, ﬁndings from the present study indicate that patients may ﬁnd it
easier to admit to forgetting than skipping because they feel they are more likely to be ‘told
oﬀ’ if they admit to intentionally skipping treatments.
The increasingly ﬂexible approach to prophylaxis, which gives some patients the
freedom to change the timing of their injections, is likely to make it more complicated
to keep track of when injections are due. Rather than following a strict routine, in
which injections are done on the same day each week, or every other day, patients with
a ﬂexible regimen will need to manage their treatment actively, remembering when the
last treatment was done and when the next one is due. Not having a well-established
routine may lead to unintentional non-adherence in some cases. A more ﬂexible approach
to prophylaxis can also make it more challenging for the haemophilia team to ascertain the
extent to which individual patients are adhering to their regimen. Going forward, dichot-
omising non-adherent patients into ‘forgetters’ and ‘skippers’ may not very useful when
designing interventions aimed at improving adherence. As regimens are often tailored,
it follows that approaches aimed at improving adherence may also need to be tailored
around individual circumstances. It appears that in many circumstances this is already
the case, as haemophilia teams tend to work with individual patients in a way that suits
their personal situation.
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Another important development to consider in relation to adherence to prophylaxis is
the recent introduction of extended half-life factor products, which can signiﬁcantly
reduce the number of intravenous infusions needed, whilst also in many patients aim
for increased protection from debilitating bleeding events (need to add reference). Switch-
ing to a regimen with less frequent injections is likely to facilitate the use of prophylaxis in
patients with poor venous access and may perhaps increase adherence among some
patients due to the reduced treatment burden. However, it may reduce adherence in
other patients, for instance those who are more likely to forget if they do not follow a
strict routine.
The personalised approach to prophylaxis raises some interesting questions in relation
to adherence. In some instances behaviour that would have been considered non-adherent
just a few years ago (e.g. reducing number of injections during a ‘quiet’ week), may now be
seen as an acceptable adjustment. Equally, the deﬁnition of ‘over-treating’ may also need
to be revised, as patients who increase the dose or frequency of their injections to accom-
modate a more active lifestyle are not necessarily over-treating. This has some important
implications for patient education and information, adherence assessment and research,
and haemophilia care. Patient education about treatment is likely to become more com-
plicated, as tailored treatment regimens are more diﬃcult to explain and require patients
to have a better understanding of how the treatment works. Assessing adherence will also
become more complicated, as standard adherence questionnaires used in research may not
accommodate a more ﬂexible treatment, and assessment of adherence in clinical settings
will be more complicated and time-consuming.
Conclusion
The current approach that haemophilia teams follow to support patients in managing
their haemophilia treatment is working well. The increasingly ﬂexible and personalised
approach allows patients to tailor their treatment around their lifestyle and personal cir-
cumstances. This in turn motivates them to keep on track with their treatment, which in
turn results in reduced bleeding episodes and its associated costs for patients, the NHS,
and the wider society. Personalised prophylaxis dosing, both in terms of timing and phar-
macokinetic-guided dosing is increasingly relevant in haemophilia centres. However, this
ﬂexible approach can also lead to some confusion around treatment frequency, dosing and
may lead to accidental non-adherence. Some additional training and education of patients
and their families to increase their knowledge and skills around prophylaxis may help to
improve adherence, and thus protection, among those patients who currently miss
occasional treatments due to misunderstanding personalised-tailoring around their
activities.
Acknowledgements
The research received peer-reviewed funding from the Bayer Haemophilia Awards Programme
(Caregiver Award awarded to the ﬁrst author). The authors would like to thank Dr T. Biss at New-
castle Haemophilia Comprehensive Care Centre, Prof P. Collins at Arthur Bloom Haemophilia
Centre at University, Hospital of Wales, Dr J. Motwani and Dr M. Williams at Birmingham Chil-
dren’s Hospital Haemophilia Unit, and Dr J. Wilde at West Midlands Adult Comprehensive Care
Haemophilia & Thrombosis Centre. Thanks also go to the dedicated research staﬀ (including
HEALTH PSYCHOLOGY AND BEHAVIORAL MEDICINE 297
nurses and allied health professionals), who helped with identifying eligible patients and arranging
consent to participate in the study.
Disclosure statement
Dr Hart, Dr Troop and Dr van Os are currently involved in research funded by Baxalta (part of
Shire). Dr Hart has received research support from Bayer (Early Career Investigator Award) and
Octapharma; travel support from Octapharma and honoraria from Baxter, Bayer, Novo Nordisk
and Pﬁzer. Dr van Os has received travel support and honoraria from Bayer.
Funding
This work was supported by Bayer Haemophilia Awards [Caregiver Award].
References
Ahlberg, Å. (1965). Haemophilia in Sweden VII. Incidence, treatment and prophylaxis of arthro-
pathy and other musculo-skeletal manifestations of haemophilia A and B. Acta Orthopaedica
Scandinavica, 36(suppl. 77), 3–132. doi:10.3109/ort.1965.36.suppl-77.01
Alvin, P., Rey, C., & Frappier, J. Y. (1995). Compliance thérapeutique chez l’adolescent malade
chronique. Archives de Pédiatrie, 2(9), 874–882. doi:10.1016/0929-693X(96)81267-X
Arias Llorente, R. P., Bousoño García, C., & Díaz Martín, J. J. (2008). Treatment compliance in chil-
dren and adults with cystic ﬁbrosis. Journal of Cystic Fibrosis, 7(5), 359–367. doi:10.1016/j.jcf.
2008.01.003
Ar Muhlis, C., Vaide, I., Berntorp, E., & Björkman, S. (2014). Methods for individualising factor
VIII dosing in prophylaxis. European Journal of Haematology, 93(s76), 16–20. doi:10.1111/ejh.
12370
Bolton-Maggs, P. H. B., & Pasi, K. J. (2003). Haemophilias A and B. The Lancet, 361(9371), 1801–
1809. Retrieved from http://linkinghub.elsevier.com/retrieve/pii/S0140673603134058
Collins, P. W. (2012). Personalized prophylaxis. Haemophilia, 18(4), 131–135. doi:10.1111/j.1365-
2516.2012.02838.x
Collins, P. W., Blanchette, V. S., Fischer, K., BjÖRkman, S., Oh, M., Fritsch, S.,…On Behalf Of The
Rahf-Pfm Study, G. (2009). Break-through bleeding in relation to predicted factor VIII levels in
patients receiving prophylactic treatment for severe hemophilia A. Journal of Thrombosis and
Haemostasis, 7(3), 413–420. doi:10.1111/j.1538-7836.2008.03270.x
Coppola, A., Di Capua, M., & De Simone, C. (2008). Primary prophylaxis in children with haemo-
philia. Blood Transfusion, 6(2), s11–s11. doi:10.2450/2008.0030-08
De Moerloose, P., Urbancik, W., Van Den Berg, H. M., & Richards, M. (2008). A survey of adher-
ence to haemophilia therapy in six European countries: Results and recommendations.
Haemophilia, 14(5), 931–938. doi:10.1111/j.1365-2516.2008.01843.x
Den Uijl, I., Mauser Bunschoten, E., Roosendaal, G., Schutgens, R., Biesma, D., Grobbee, D., &
Fischer, K. (2011). Clinical severity of haemophilia A: Does the classiﬁcation of the 1950s still
stand? Haemophilia, 17(6), 849–853. doi:10.1111/j.1365-2516.2011.02539.x
DiMatteo, M. R. (2004). Variations in patients? Adherence to medical recommendations. Medical
Care, 42(3), 200–209. doi:10.1097/01.mlr.0000114908.90348.f9
Duncan, N., Kronenberger, W., Roberson, C., & Shapiro, A. (2010). VERITAS-Pro: A new measure
of adherence to prophylactic regimens in haemophilia. Haemophilia, 16(2), 247–255. doi:10.
1111/j.1365-2516.2009.02129.x
du Treil, S., Rice, J., & Leissinger, C. A. (2007). Quantifying adherence to treatment and its relation-
ship to quality of life in a well-characterized haemophilia population. Haemophilia, 13(5), 493–
501. doi:10.1111/j.1365-2516.2007.01526.x
Farrugia, A., Gringeri, A., & von Mackensen, S. (2018). The multiple beneﬁts of sport in haemo-
philia. Haemophilia, 24(3), 341–343. doi:10.1111/hae.13496
298 S. VAN OS ET AL.
Feeling angry? Frustrated? Anxious? Low? Haemophilia Society website. Retrieved from http://
haemophilia.org.uk/support/day-day-living/patient-support/healthy-living/positive-mental-
health/on 10-06-2018
Fischer, K. (2012). Prophylaxis for adults with haemophilia: One size does not ﬁt all. Blood
Transfusion, 10(2), 169–173. doi:10.2450/2012.0174-11
Fischer, K., Astermark, J., van der Bom, J. G., Ljung, R., Berntop, E, Grobbee, D. E., & van den Berg,
H. M. (2002). Prophylactic treatment for severe haemophilia: comparison of an intermediate‐
dose to a high‐dose regimen. Haemophilia, 8, 753–760. doi:10.1046/j.1365-2516.2002.00694.x
Gallant, M. P. (2003). The inﬂuence of social support on chronic illness self-management: A review
and directions for research. Health Education & Behavior, 30(2), 170–195. doi:10.1177/
1090198102251030
Gringeri, A., Doralt, J., Valentino, L. A., Crea, R., & Reininger, A. J. (2016). An innovative outcome-
based care and procurement model of hemophilia management. Expert Review of
Pharmacoeconomics & Outcomes Research, 16(3), 337–345. doi:10.1080/14737167.2016.1178066
Griva, K., Myers, L. B., & Newman, S. (2000). Illness perceptions and self eﬃcacy beliefs in adoles-
cents and young adults with insulin dependent diabetes mellitus. Psychology & Health, 15(6),
733–750. doi:10.1080/08870440008405578
Hacker, M., Geraghty, S., & Manco-Johnson, M. (2001). Barriers to compliance with prophylaxis
therapy in haemophilia. Haemophilia, 7(4), 392–396.
Horne, R., & Weinman, J. (1999). Patients’ beliefs about prescribed medicines and their role in
adherence to treatment in chronic physical illness. Journal of Psychosomatic Research, 47(6),
555–567. doi:10.1016/S0022-3999(99)00057-4
Howell, C., Scott, K., & Patel, D. R. (2017). Sports participation recommendations for patients with
bleeding disorders. Translational Pediatrics, 6(3), 174–180. doi:10.21037/tp.2017.04.07
Iannotti, R. J., Schneider, S., Nansel, T. R., Haynie, D. L., Plotnick, L. P., Clark, L. M., & Simons-
Morton, B. (2006). Self-eﬃcacy, outcome expectations, and diabetes self-management in adoles-
cents with type 1 diabetes. Journal of Developmental and Behavioral Pediatrics, 27(2), 98–105.
doi:10.1097/00004703-200604000-00003
Khair, K. (2013). Supporting adherence and improving quality of life in haemophilia care. British
Journal of Nursing, 22(12), 692.
Khair, K., & Holland, M. (2013). Managing hemophilia: The role of mobile technology. Smart
Homecare Technology and TeleHealth, 2, 39–44.
KyngÄs, H. A., Kroll, T., & Duﬀy, M. E. (2000). . Compliance in adolescents with chronic diseases: a
review. Journal of Adolescent Health, 26(6), 379–388. doi:10.1016/S1054-139X(99)00042-7
La Greca, A. M., & Bearman, K. J. (2002). The diabetes social support questionnaire-family version:
Evaluating adolescents’ diabetes-speciﬁc support from family members. Journal of Pediatric
Psychology, 27(8), 665–676. doi:10.1093/jpepsy/27.8.665
La Greca, A. M., La Greca, A. M., Auslander, W. F., Auslander, W. F., Greco, P., Greco, P., &
Santiago, J. V. (1995). I get by with a little help from my family and friends: Adolescents’
support for diabetes care. Journal of Pediatric Psychology, 20(4), 449–476. doi:10.1093/jpepsy/
20.4.449
Ljung, R. (2009). Prophylactic therapy in haemophilia. Blood Reviews, 23(6), 267–274. doi:10.1016/
j.blre.2009.08.001
Llewellyn, C. D., Miners, A. H., Lee, C. A., Harrington, C., & Weinman, J. (2003). The illness per-
ceptions and treatment beliefs of individuals with severe haemophilia and their role in adherence
to home treatment. Psychology & Health, 18(2), 185–200. doi:10.1080/0887044031000098198
Makris, M. (2012). Prophylaxis in haemophilia should be life-long. Blood Transfusion, 10(2), 165–
168. doi:10.2450/2012.0147-11
Manco-Johnson, M. J., Abshire, T. C., Shapiro, A. D., Riske, B., Hacker, M. R., Kilcoyne, R., & Evatt,
B. (2007). Prophylaxis versus episodic treatment to prevent joint disease in boys with severe
hemophilia. New England Journal of Medicine, 357(6), 535–544. doi:10.1056/NEJMoa067659
McQuaid, E. L., Kopel, S. J., Klein, R. B., & Fritz, G. K. (2003). Medication adherence in pediatric
asthma: Reasoning, responsibility, and behavior. Journal of Pediatric Psychology, 28(5), 323–333.
doi:10.1093/jpepsy/jsg022
HEALTH PSYCHOLOGY AND BEHAVIORAL MEDICINE 299
Miners, A. (2009). Revisiting the cost-eﬀectiveness of primary prophylaxis with clotting factor for
the treatment of severe haemophilia A. Haemophilia, 15(4), 881–887.
Nilsson, I. M. (1993). Experience with prophylaxis in Sweden. Seminars in Hematology, 30(3 Suppl.
2), 16–19.
Nilsson, I. M., Berntop, E., Lofqvist, T., & Pettersson, H. (1992). Twenty-ﬁve years’ experience of
prophylactic treatment in severe haemophilia A and B. Journal of Internal Medicine, 232(1),
25–32. doi:10.1111/j.1365-2796.1992.tb00546.x
Omura, K., Ito, M., Eguchi, E., Imahuku, K., Kutsumi, M., Inoue, Y., & Yamazaki, Y. (2013). The
eﬀect of peer support groups on self-care for haemophilic patients with HIV in japan.
Haemophilia, 19(6), 876–881. doi:10.1111/hae.12222
Ott, J., Greening, L., Palardy, N., Holderby, A., & DeBell, W. K. (2000). Self-Eﬃcacy as a mediator
variable for adolescents’ adherence to treatment for insulin-dependent diabetes mellitus.
Children’s Health Care, 29(1), 47–63. doi:10.1207/S15326888CHC2901_4
Panicker, J., Warrier, I., Thomas, R., & Lusher, J. (2003). The overall eﬀectiveness of prophylaxis in
severe haemophilia. Haemophilia, 9(3), 272–278.
Reid, K., Flowers, P., & Larkin, M. (2005). Exploring lived experience. The Psychologist, 18(1), 20–
23.
Richards, M., Williams, M., Chalmers, E., Liesner, R., Collins, P., Vidler, V.,… Paediatric Working
Party of the United Kingdom Haemophilia Doctors, O. (2010). A United Kingdom haemophilia
centre doctors’ organization guideline approved by the British committee for standards in hae-
matology: Guideline on the use of prophylactic factor VIII concentrate in children and adults
with severe haemophilia A. British Journal of Haematology, 149(4), 498–507. doi:10.1111/j.
1365-2141.2010.08139.x
Salema, N.-E. M., Elliott, R. A., & Glazebrook, C. (2011). A systematic review of adherence-enhan-
cing interventions in adolescents taking long-term medicines. Journal of Adolescent Health, 49
(5), 455–466. doi:10.1016/j.jadohealth.2011.02.010
Schrijvers, L. H., Uitslager, N., Schuurmans, M. J., & Fischer, K. (2013). Barriers and motivators of
adherence to prophylactic treatment in haemophilia: A systematic review. Haemophilia, 19(3),
355–361. doi:10.1111/hae.12079
Shaw, R. J. (2001). Treatment adherence in adolescents: Development and psychopathology.
Clinical Child Psychology and Psychiatry, 6(1), 137–150. doi:10.1177/1359104501006001011
Smith, J. A. (2003). Qualitative psychology: A practical guide to research methods. London: Sage.
Smith, J. A. (2010). Interpretative phenomenological analysis: A reply to Amedeo Giorgi. Existential
Analysis. Existential Analysis: Journal of the Society for Existential Analysis, 21(2), 186–192.
Smith, J., Flowers, P., & Larkin, M. (2009). Interpretative phenomenological analysis: Theory,
method and research. Los Angeles. CA: Sage.
Smith, J. A., & Osborn, M. (2003). Interpretative phenomenological analysis. In J. A. Smith (Ed.),
Qualitative psychology: A practical guide to research methods (pp. 53–80). London: Sage.
Thornburg, C. D. (2008). Physicians’ perceptions of adherence to prophylactic clotting factor infu-
sions. Haemophilia, 14(1), 25–29. doi:10.1111/j.1365-2516.2007.01591.x
van Os, S., Troop, N., Sullivan, K., & Hart, D. (2017). Adherence to prophylaxis in adolescents and
young adults with severe haemophilia: A quantitative study with patients. PLoS One, 12(1),
e0169880. doi:10.1371/journal.pone.0169880
Witmer, C., Presley, R., Kulkarni, R., Michael Soucie, J., Manno, C. S., & Raﬃni, L. (2011).
Associations between intracranial haemorrhage and prescribed prophylaxis in a large cohort
of haemophilia patients in the United States. British Journal of Haematology, 152(2), 211–216.
doi:10.1111/j.1365-2141.2010.08469.x
Yardley, L. (2000). Dilemmas in qualitative health research. Psychology & Health, 15(2), 215–228.
doi:10.1080/08870440008400302
Yardley, L. (2008). Demonstrating validity in qualitative psychology. Qualitative Psychology: A
Practical Guide to Research Methods, 2, 235–251.
300 S. VAN OS ET AL.
